BDRXBiodexa Pharmaceuticals Plc

Nasdaq midatechpharma.com


$ 1.08 $ 0.05 (4.85 %)    

Tuesday, 28-May-2024 15:49:25 EDT
QQQ $ 454.82 $ 1.73 (0.38 %)
DIA $ 398.57 $ -2.04 (-0.52 %)
SPY $ 530.36 $ 0.37 (0.07 %)
TLT $ 91.26 $ -1.31 (-1.43 %)
GLD $ 225.37 $ 2.27 (1.05 %)
$ 1.08
$ 1.01
$ 0.00 x 0
$ 0.00 x 0
$ 1.01 - $ 1.11
$ 0.67 - $ 11.19
496,725
na
1.28B
$ 1.25
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 biodexa-pharmaceuticals-stock-is-tumbling-wednesday-whats-going-on

Biodexa announced the exercise of previously issued warrants and an agreement between the company and several investors to exer...

 biodexa-announces-7m-of-gross-proceeds-from-warrant-exercises-and-an-agreement-between-the-company-and-several-accredited-investors-to-exercise-certain-existing-series-e-warrants-and-series-f-warrants-to-purchase-up-to-an-aggregate-of-4358322-adss

Biodexa Announces $7 Million of Gross Proceeds from Warrant ExercisesProceeds Cover Year 1 eRapa Phase 3 Obligations, Unlocking...

 whats-going-on-with-biodexa-pharmaceuticals-stock

Biodexa Pharmaceuticals (NASDAQ:BDRX) stock is trading higher. The company on Tuesday announced progress towards the treatment ...

Core News & Articles
Market-Moving News for May 21st
05/21/2024 12:42:13

BDRX: 110% | Biodexa Pharmaceuticals Presents Phase 2 Clinical Trial Results Of Its Newly-Licensed eRapa In Familial Adenomatou...

 biodexa-pharmaceuticals-presents-phase-2-clinical-trial-results-of-its-newly-licensed-erapa-in-familial-adenomatous-polyposis-scheduled-for-presentation-at-the-2024-digestive-disease-week-annual-meeting-reports-overall-83-non-progression-rate-at-6-months

Biodexa Pharmaceuticals PLC("Biodexa" or the "Company")Positive Statistically Significant Phase 2 Clinical Tria...

 biodexas-licensor-emtora-to-announce-phase-2-clinical-trial-results-of-erapa-in-familial-adenomatous-polyposis-to-be-presented-at-prestigious-2024-digestive-disease-week-annual-meeting

Biodexa's Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Pres...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION